Bayer's Triple Test: A Crucial Month for the German Conglomerate

Bayer faces a pivotal 4-week period with its AGM, a landmark US Supreme Court hearing on glyphosate litigation, and Q1 earnings. The outcomes will define its legal and financial trajectory.

Bayer shares are bracing for a defining period. Over the next four weeks, the German life sciences group faces a dense calendar of events, each capable of moving the stock. This critical stretch begins with an annual meeting, pivots to a landmark US Supreme Court hearing, and culminates in the first-quarter earnings report, setting the stage for the company's trajectory.

The virtual Annual General Meeting on April 24th will see a proposed dividend of 0.11 euros per share, unchanged from the previous year. This signal of continuity is notable given the company's projected free cash flow of approximately minus five billion euros for 2026. The ex-dividend date is set for April 27th, with payment scheduled for April 29th. The meeting will also oversee a supervisory board reshuffle, with Marcel Smits and Alfred Stern, the CEO of OMV, nominated to succeed Paul Achleitner and Colleen Goggins.

Just three days later, the focus shifts to Washington D.C. Oral arguments in the case Durnell v. Monsanto are scheduled before the US Supreme Court on April 27th. This hearing is pivotal, as it could reshape the legal landscape for the entire wave of glyphosate litigation. Bayer’s core argument is that the federal FIFRA law preempts state-level cancer warning requirements for product labels. A favorable ruling would undermine the legal basis for thousands of future claims. The Trump administration supports Bayer's position, marking a clear shift from the Biden era.

However, opposition is mounting. Attorneys general from Texas, Florida, and Ohio have filed amicus briefs in opposition, with a total of 18 such briefs submitted. Since acquiring Monsanto in 2018, Bayer has paid over $11 billion in settlements and judgments and has provisions of 11.8 billion euros on its books. A final ruling is expected by summer. In a parallel development, a judge in Missouri has preliminarily approved a $7.25 billion class-action settlement on the state level. Kentucky also recently became the third US state to pass a law shielding Bayer from certain glyphosate claims.

Amid these legal battles, the company maintains its operational guidance. Management reaffirms its 2026 EBITDA target of 9.6 to 10.1 billion euros, stating that potential US import tariffs on pharmaceuticals are already factored into the annual plan, as existing agreements cap the impact at 15 percent. The pharmaceuticals division recently secured key approvals: Eylea 8 mg in Japan and Kerendia in the EU for treating heart failure.

This flurry of activity precedes the company's quiet period ahead of the Q1 results on May 12th. The earnings report will provide the first official management commentary following the Supreme Court hearings, serving as a key gauge of Bayer's own assessment of its legal position. Financially, pressures persist. Free cash flow fell 32.9 percent in 2025 to 2.1 billion euros, while net financial debt stood at 29.8 billion euros.

Analyst sentiment has shown a flicker of improvement. DZ Bank recently upgraded its rating on Bayer from "Sell" to "Hold," raising its price target from 42 to 44 euros. The bank cited increasing calculability of glyphosat litigation risks and a refocus on operational performance. With the stock trading around 40 euros, this implies limited near-term upside but removes a clear sell signal. The shares currently trade about 18 percent below their 52-week high, yet have doubled in value over a twelve-month period, underscoring the volatile re-rating at play. The 40-euro mark remains a key technical anchor in the chart as investors navigate this decisive month.